DATA Shows BENEFIT OF ALIMTA FOR (Asia Pulse via Yahoo!7 News)
NON-SMALL CELL LUNG CANCER (Full text of a statement. Contact details follow below.) DATA AFFIRM BENEFIT OF ALIMTA (PEMETREXED FOR INJECTION) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER SEOUL, Sept. 3 /PRNewswire-AsiaNet/ -- The clinical benefit of ALIMTA(R) (pemetrexed for injection) continues to be validated across patient populations, as demonstrated in two studies conducted in Asia. The ...

Data Affirm Benefit of ALIMTA(R) (pemetrexed for injection) for Patients with Non-Small Cell Lung Cancer (Press Trust of India)
The clinical benefit of ALIMTA(R) (pemetrexed for injection) continues to be validated across patient populations, as demonstrated in two studies conducted in Asia. The data presented today at the 12th World Conference on Lung Cancer provide further support of the efficacy of Eli Lilly and Company's ALIMTA in treating non-small cell lung cancer (NSCLC), the world's most common form of cancer.(1) ...

Out-licensing opportunities (Pharmalicencing)
ETHYPHARM is a pharmaceutical company which develops oral modified release formulations through its patented technologies. It focuses on developing, manufacturing and licensing pharmaceutical products based on optimization of delivery through proprietary technologies.